STOCK TITAN

[8-K] LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Comerica Inc. (CMA) filed a Form 4 showing that director Ximena G. Humrichouse received 1,875 restricted stock units (RSUs) on 07/29/2025 under the company’s Long-Term Incentive Plan. The award is coded “A” (acquisition) at $0 cost, indicating a non-cash equity grant rather than an open-market purchase. The RSUs vest 100% on the grant date and will generally convert into an equal number of common shares one year after the director leaves the Board.

After the grant, Humrichouse’s direct beneficial ownership increased to 47,688 CMA shares. No derivative securities were reported, and there were no sales or option exercises disclosed. The transaction reflects routine director compensation and has minimal impact on Comerica’s share count or near-term financial outlook.

Comerica Inc. (CMA) ha presentato un Modulo 4 che mostra che la direttrice Ximena G. Humrichouse ha ricevuto 1.875 unità azionarie vincolate (RSU) il 29/07/2025 nell’ambito del Piano di Incentivi a Lungo Termine della società. Il premio è codificato come “A” (acquisizione) a costo zero, indicando una concessione azionaria non in denaro anziché un acquisto sul mercato aperto. Le RSU maturano al 100% alla data di assegnazione e generalmente si convertiranno in un numero uguale di azioni ordinarie un anno dopo che la direttrice lascerà il Consiglio.

Dopo l’assegnazione, la proprietà diretta di Humrichouse è aumentata a 47.688 azioni CMA. Non sono stati segnalati titoli derivati né vendite o esercizi di opzioni. La transazione riflette una normale compensazione per i direttori e ha un impatto minimo sul numero di azioni di Comerica o sulle prospettive finanziarie a breve termine.

Comerica Inc. (CMA) presentó un Formulario 4 que muestra que la directora Ximena G. Humrichouse recibió 1,875 unidades restringidas de acciones (RSU) el 29/07/2025 bajo el Plan de Incentivos a Largo Plazo de la compañía. La concesión está codificada como “A” (adquisición) a costo cero, lo que indica una asignación de acciones sin efectivo en lugar de una compra en el mercado abierto. Las RSU se consolidan al 100% en la fecha de concesión y generalmente se convertirán en un número igual de acciones ordinarias un año después de que la directora deje la Junta.

Después de la concesión, la propiedad directa de Humrichouse aumentó a 47,688 acciones de CMA. No se reportaron valores derivados ni ventas o ejercicios de opciones. La transacción refleja una compensación rutinaria para directores y tiene un impacto mínimo en el recuento de acciones de Comerica o en las perspectivas financieras a corto plazo.

Comerica Inc. (CMA)는 이사 Ximena G. Humrichouse가 2025년 7월 29일 회사의 장기 인센티브 계획에 따라 1,875개의 제한 주식 단위(RSU)를 받았음을 나타내는 Form 4를 제출했습니다. 이 보상은 0달러 비용의 “A”(취득) 코드로 표시되어 현금이 아닌 주식 부여임을 의미하며, 공개 시장에서의 구매가 아닙니다. RSU는 부여일에 100% 베스팅되며, 일반적으로 이사가 이사회에서 물러난 후 1년 후에 동일한 수의 보통주로 전환됩니다.

부여 후 Humrichouse의 직접 소유 주식은 47,688주 CMA로 증가했습니다. 파생 증권 보고나 매도 및 옵션 행사 내역은 없었습니다. 이 거래는 이사 보상으로 일상적인 것이며 Comerica의 주식 수나 단기 재무 전망에 미치는 영향이 거의 없습니다.

Comerica Inc. (CMA) a déposé un formulaire 4 indiquant que la directrice Ximena G. Humrichouse a reçu 1 875 unités d’actions restreintes (RSU) le 29/07/2025 dans le cadre du Plan d’Incitation à Long Terme de l’entreprise. Cette attribution est codée « A » (acquisition) à coût nul, ce qui indique une attribution d’actions non monétaire plutôt qu’un achat sur le marché libre. Les RSU sont acquises à 100 % à la date d’attribution et se convertiront généralement en un nombre égal d’actions ordinaires un an après le départ de la directrice du conseil.

Après cette attribution, la détention directe de Humrichouse est passée à 47 688 actions CMA. Aucun titre dérivé n’a été déclaré, et aucune vente ni exercice d’option n’a été divulgué. Cette opération reflète une rémunération habituelle des administrateurs et a un impact minimal sur le nombre d’actions de Comerica ou sur les perspectives financières à court terme.

Comerica Inc. (CMA) reichte ein Formular 4 ein, das zeigt, dass die Direktorin Ximena G. Humrichouse am 29.07.2025 1.875 beschränkte Aktieneinheiten (RSUs) im Rahmen des langfristigen Anreizplans des Unternehmens erhalten hat. Die Zuteilung ist mit „A“ (Erwerb) zu 0 $ Kosten codiert, was auf eine nicht-barwertige Aktienzuteilung und keinen Kauf am offenen Markt hinweist. Die RSUs werden zu 100 % am Gewährungsdatum unverfallbar und wandeln sich in der Regel ein Jahr nach dem Ausscheiden der Direktorin aus dem Vorstand in eine gleiche Anzahl von Stammaktien um.

Nach der Zuteilung erhöhte sich Humrichouses direkte Beteiligung auf 47.688 CMA-Aktien. Es wurden keine derivativen Wertpapiere gemeldet und keine Verkäufe oder Optionsausübungen offengelegt. Die Transaktion stellt eine routinemäßige Vergütung für Direktoren dar und hat geringe Auswirkungen auf die Aktienanzahl von Comerica oder die kurzfristige Finanzprognose.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU grant; immaterial share count; neutral investor impact.

The filing documents a standard equity award of 1,875 RSUs to director Ximena G. Humrichouse, boosting her holdings to 47,688 shares. At roughly 0.03% of Comerica’s 132 million shares outstanding, dilution is negligible. The RSUs settle post-service, aligning director incentives with long-term performance. No cash changed hands and no derivatives were created or exercised. Given the modest size and absence of market transactions, I view the disclosure as not impactful for valuation or trading decisions.

Comerica Inc. (CMA) ha presentato un Modulo 4 che mostra che la direttrice Ximena G. Humrichouse ha ricevuto 1.875 unità azionarie vincolate (RSU) il 29/07/2025 nell’ambito del Piano di Incentivi a Lungo Termine della società. Il premio è codificato come “A” (acquisizione) a costo zero, indicando una concessione azionaria non in denaro anziché un acquisto sul mercato aperto. Le RSU maturano al 100% alla data di assegnazione e generalmente si convertiranno in un numero uguale di azioni ordinarie un anno dopo che la direttrice lascerà il Consiglio.

Dopo l’assegnazione, la proprietà diretta di Humrichouse è aumentata a 47.688 azioni CMA. Non sono stati segnalati titoli derivati né vendite o esercizi di opzioni. La transazione riflette una normale compensazione per i direttori e ha un impatto minimo sul numero di azioni di Comerica o sulle prospettive finanziarie a breve termine.

Comerica Inc. (CMA) presentó un Formulario 4 que muestra que la directora Ximena G. Humrichouse recibió 1,875 unidades restringidas de acciones (RSU) el 29/07/2025 bajo el Plan de Incentivos a Largo Plazo de la compañía. La concesión está codificada como “A” (adquisición) a costo cero, lo que indica una asignación de acciones sin efectivo en lugar de una compra en el mercado abierto. Las RSU se consolidan al 100% en la fecha de concesión y generalmente se convertirán en un número igual de acciones ordinarias un año después de que la directora deje la Junta.

Después de la concesión, la propiedad directa de Humrichouse aumentó a 47,688 acciones de CMA. No se reportaron valores derivados ni ventas o ejercicios de opciones. La transacción refleja una compensación rutinaria para directores y tiene un impacto mínimo en el recuento de acciones de Comerica o en las perspectivas financieras a corto plazo.

Comerica Inc. (CMA)는 이사 Ximena G. Humrichouse가 2025년 7월 29일 회사의 장기 인센티브 계획에 따라 1,875개의 제한 주식 단위(RSU)를 받았음을 나타내는 Form 4를 제출했습니다. 이 보상은 0달러 비용의 “A”(취득) 코드로 표시되어 현금이 아닌 주식 부여임을 의미하며, 공개 시장에서의 구매가 아닙니다. RSU는 부여일에 100% 베스팅되며, 일반적으로 이사가 이사회에서 물러난 후 1년 후에 동일한 수의 보통주로 전환됩니다.

부여 후 Humrichouse의 직접 소유 주식은 47,688주 CMA로 증가했습니다. 파생 증권 보고나 매도 및 옵션 행사 내역은 없었습니다. 이 거래는 이사 보상으로 일상적인 것이며 Comerica의 주식 수나 단기 재무 전망에 미치는 영향이 거의 없습니다.

Comerica Inc. (CMA) a déposé un formulaire 4 indiquant que la directrice Ximena G. Humrichouse a reçu 1 875 unités d’actions restreintes (RSU) le 29/07/2025 dans le cadre du Plan d’Incitation à Long Terme de l’entreprise. Cette attribution est codée « A » (acquisition) à coût nul, ce qui indique une attribution d’actions non monétaire plutôt qu’un achat sur le marché libre. Les RSU sont acquises à 100 % à la date d’attribution et se convertiront généralement en un nombre égal d’actions ordinaires un an après le départ de la directrice du conseil.

Après cette attribution, la détention directe de Humrichouse est passée à 47 688 actions CMA. Aucun titre dérivé n’a été déclaré, et aucune vente ni exercice d’option n’a été divulgué. Cette opération reflète une rémunération habituelle des administrateurs et a un impact minimal sur le nombre d’actions de Comerica ou sur les perspectives financières à court terme.

Comerica Inc. (CMA) reichte ein Formular 4 ein, das zeigt, dass die Direktorin Ximena G. Humrichouse am 29.07.2025 1.875 beschränkte Aktieneinheiten (RSUs) im Rahmen des langfristigen Anreizplans des Unternehmens erhalten hat. Die Zuteilung ist mit „A“ (Erwerb) zu 0 $ Kosten codiert, was auf eine nicht-barwertige Aktienzuteilung und keinen Kauf am offenen Markt hinweist. Die RSUs werden zu 100 % am Gewährungsdatum unverfallbar und wandeln sich in der Regel ein Jahr nach dem Ausscheiden der Direktorin aus dem Vorstand in eine gleiche Anzahl von Stammaktien um.

Nach der Zuteilung erhöhte sich Humrichouses direkte Beteiligung auf 47.688 CMA-Aktien. Es wurden keine derivativen Wertpapiere gemeldet und keine Verkäufe oder Optionsausübungen offengelegt. Die Transaktion stellt eine routinemäßige Vergütung für Direktoren dar und hat geringe Auswirkungen auf die Aktienanzahl von Comerica oder die kurzfristige Finanzprognose.

false 0000948320 0000948320 2025-07-31 2025-07-31 0000948320 LFMD:CommonStockParValue0.01PerShareMember 2025-07-31 2025-07-31 0000948320 LFMD:Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember 2025-07-31 2025-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 31, 2025

 

LIFEMD, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-39785   76-0238453

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

236 Fifth Avenue, Suite 400

New York, NY 10001

(Address of principal executive offices, including zip code)

 

(866) 351-5907

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   LFMD   The Nasdaq Global Market
8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share   LFMDP   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 31, 2025, LifeMD, Inc. (the “Company”) publicly announced the appointment of Shayna Webb Dray as the Chief Operating Officer of the Company effective March 27, 2025.

 

Shayna Webb Dray, age 38, is an accomplished operations and supply chain executive with over 15 years of experience in transforming operations within high-growth and established organizations. Her expertise lies in driving improved outcomes and reducing costs through process optimization and collaborative team building. Ms. Webb Dray is dedicated to continuous improvement, creating quality experiences, and implementing innovative solutions, consistently delivering significant annual savings and enhanced process function.

 

Prior to her appointment as Chief Operating Officer of the Company, Ms. Webb Dray served as the Senior Vice President of Operations of the Company from September 2023 to July 2025. In this role, she was responsible for the launch and subsequent scaling of the Company’s weight management program, as well as overseeing day-to-day management of the Care Center, Pharmacy, Clinical Operations, and the Project Management Office. Ms. Webb Dray previously served as the Head of Supply Chain & Procurement of the Company from May 2021 to September 2023, where she spearheaded the creation of a comprehensive supply chain strategy. Before that, as the Executive Director of Operations at Kaplan Publishing, a subsidiary of Graham Holdings Company, from March 2016 to May 2021, she generated substantial annual savings through supply chain optimization and advised on key operational and strategic initiatives.

 

Ms. Webb Dray holds a Bachelor of Science in Supply Chain Management and Marketing from Syracuse University, where she was a Brethen Scholar.

 

There are no family relationships between Ms. Webb Dray and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company. There are no related party transactions between the Company and Ms. Webb Dray reportable under Item 404(a) of Regulation S-K.

 

In connection with Ms. Webb Dray’s appointment as Chief Operating Officer of the Company, the Company and Ms. Webb Dray entered into a Third Amendment, dated July 27, 2025, to the Confidential Offer Letter between the Company and Ms. Webb Dray, dated April 14, 2021, as amended on November 8, 2023 and May 7, 2024 (as amended, the “Employment Agreement”), pursuant to which Ms. Webb Dray receives a base salary of $400,000. On July 27, 2025, the Company and Ms. Webb Dray also entered into a Restricted Stock Unit Award Agreement, pursuant to which she received 100,000 restricted stock units (“RSUs”), of which (i) 10,000 RSUs will vest on January 1, 2026, (ii) 20,000 RSUs will vest on January 1, 2027, (iii) 20,000 RSUs will vest on January 1, 2028, (iv) 25,000 RSUs will vest on the Company’s healthcare business achieving certain annualized EBITDA targets, on or before December 31, 2027, and (v) 25,000 RSUs will vest on the Company’s healthcare business achieving certain annualized EBITDA targets, on or before December 31, 2027.

 

Upon termination of Ms. Webb Dray’s employment with the Company without “Cause” or for “Good Reason,” as such terms are defined in the Restricted Stock Unit Award Agreement, any then unvested, time-based Restricted Stock Units scheduled to vest in less than one year from the date of such termination shall vest in a pro rata manner. Unvested RSUs will vest immediately prior to the closing of a “Change of Control,” as defined in the Restricted Stock Unit Award Agreement. The award may be forfeited in the event of Ms. Webb Dray’s breach of certain covenants contained in the Restricted Stock Unit Award Agreement.

 

Item 5.02 of this Current Report on Form 8-K contains only a brief description of the material terms of and does not purport to be a complete description of the rights and obligations of the parties to the Employment Agreement and the Restricted Stock Unit Award Agreement, and such description is qualified in its entirety by reference to the full text of the agreements, which are filed as exhibits and incorporated by reference into this Current Report on Form 8-K.

 

 

 

 

Item 8.01 Other Events

 

On July 31, 2025, the Company issued a press release announcing the appointment of Shayna Webb Dray as the Chief Operating Officer of the Company. A copy of the press release is filed as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit   Description
     
10.1   Confidential Offer Letter, dated April 14, 2021 between LifeMD, Inc. and Shayna Webb Dray
10.2   First Amendment to Employment Agreement, dated November 8, 2023 between LifeMD, Inc. and Shayna Webb Dray
10.3   Second Amendment to Employment Agreement, dated May 7, 2024 between LifeMD, Inc. and Shayna Webb Dray
10.4   Third Amendment to Employment Agreement, dated July 27, 2025 between LifeMD, Inc. and Shayna Webb Dray
10.5   Restricted Stock Unit Award Agreement, dated July 27, 2025, between LifeMD, Inc. and Shayna Webb Dray
99.1   Press Release, dated July 31, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LIFEMD, INC.
     
Dated: July 31, 2025 By: /s/ Eric Yecies
    Eric Yecies
    Chief Legal Officer and General Counsel

 

 

 

FAQ

What insider transaction did Comerica (CMA) report on 07/29/2025?

Director Ximena G. Humrichouse acquired 1,875 restricted stock units at no cost under the Long-Term Incentive Plan.

How many CMA shares does Humrichouse own after the RSU grant?

Her direct beneficial ownership increased to 47,688 shares.

Was any cash paid for the newly acquired CMA shares?

No. The RSUs were granted at $0 as part of director compensation.

When will the RSUs convert into Comerica common stock?

They generally settle one year after the director departs the Board.

Did the filing disclose any derivative security activity?

No derivative securities were acquired, disposed, or held in this Form 4.
Lifemd, Inc.

NASDAQ:LFMDP

LFMDP Rankings

LFMDP Latest News

LFMDP Latest SEC Filings

LFMDP Stock Data

1.40M
Health Information Services
Services-offices & Clinics of Doctors of Medicine
Link
United States
NEW YORK